JPWO2006090874A1 - 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 - Google Patents
哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 Download PDFInfo
- Publication number
- JPWO2006090874A1 JPWO2006090874A1 JP2007504833A JP2007504833A JPWO2006090874A1 JP WO2006090874 A1 JPWO2006090874 A1 JP WO2006090874A1 JP 2007504833 A JP2007504833 A JP 2007504833A JP 2007504833 A JP2007504833 A JP 2007504833A JP WO2006090874 A1 JPWO2006090874 A1 JP WO2006090874A1
- Authority
- JP
- Japan
- Prior art keywords
- pattern
- disease
- cytokine
- paradigm
- response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 58
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 43
- 201000010099 disease Diseases 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims description 22
- 238000004458 analytical method Methods 0.000 title claims description 3
- 230000002265 prevention Effects 0.000 title claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 title description 3
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 210000004241 Th2 cell Anatomy 0.000 claims abstract description 8
- 210000000447 Th1 cell Anatomy 0.000 claims abstract description 7
- 210000003289 regulatory T cell Anatomy 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 39
- 230000004044 response Effects 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 26
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 17
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 17
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 17
- 108010074328 Interferon-gamma Proteins 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 102000004388 Interleukin-4 Human genes 0.000 claims description 6
- 108090000978 Interleukin-4 Proteins 0.000 claims description 6
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 6
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 229940028885 interleukin-4 Drugs 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 230000009257 reactivity Effects 0.000 claims description 2
- 230000006697 redox regulation Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000001994 activation Methods 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 abstract description 3
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 24
- 241000282472 Canis lupus familiaris Species 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 11
- 239000007787 solid Substances 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000007985 Erythema Infectiosum Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000029225 intracellular protein transport Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
5才令の雄のゴールデンレトリバー(顔面腫瘍及び左眼球突出の症状)を使用した。MR撮像によりシストを伴った腫瘤を確認し、ダイナミックMR撮像法により悪性腫瘍と診断した。
(Thサイトカイン陽性CD4陽性細胞数/CD4陽性細胞数)×100(%)、
によって定義される。
次に良性腫瘍の例について説明する。レドックス状態が酸化を呈したので、腫瘤中の活性型TGF−β1(Transforming Growth Factor-β1:Th3反応) を測定した結果は以下の通りである。
活性型あるいは潜在型Th2反応サイトカイン/TGF−β1の産生
潜在型/活性型TGF−β1 ( ng /ml )
血漿中 正常値1.70(イヌの潜在型、活性型は検出-)
血漿中 潜在型4.94 活性型 -
腫瘤内 潜在型 +↑ 活性型18.88
このような結果、治療法を変更して治療したところ活性型TGF−β1は検出されず臨床症状(治療法変更後56日現在)は著しく改善された。
次に、パラダイムパターンから、疾病の診断や予測を自動的に可能にする例について説明する。正常犬、非正常犬(悪性腫瘍、良性腫瘍や感染症など)について、実施例1に基づいて各サイトカイン反応を測定する。Th1,Th2,Th3の各軸からなる3次元の座標空間に、各サイトカインの反応量(細胞数)をトラップする。次いで、この素データを最小二乗法によって因子軸を決定する。この因子軸に直角に交わる因子軸を追加して、この二つの2次元の座標軸に基づいて、各測定値の相関係数を算出する。
正常レベル:グレーティング≦a
良性腫瘍 :a<グレーティング≦b
悪性腫瘍 :b<グレーティング
の関係を定めることができる。したがって、ある検査対象である固体についての各Th反応を測定し、その測定値に基づいてパラダイムパターンを形成して基準線を求め、これを予め定まっているグレーティングのレベルと比較することによって、外科的な検査や遺伝子診断などの、本願発明の検査項目として説明されたもの以外の検査を行うことなしに、検査固体の疾病診断或いは将来の発症を予見することができる。なお、グレーティングのレベルの決定に必要な検査対象固体として、種別、体重別、年齢別、性別などの区別は必要ではないが、ある項目について検査対象固体を区別してもよい。
図5は、実施例1と同様にして得た、良性腫瘍の場合におけるパラダイムパターンである。表現型Th1/Th2/Th3反応、細胞内在型Th1/Th2/Th3反応のいずれにおいても、Th3の割合が少ないことが分かる。即ち、既述のグレーティングの評価とTh3の割合の評価によって、悪性腫瘍と良性腫瘍の区別をTh反応のパラダイムパターンから可能になることが分かる。なお、悪性腫瘍および良性腫瘍の場合のパラダイムパターンにおいて、Th1に対してTh2の値が増加している点において共通するものの、Th3の値については、後者のものが前者のものに比較して顕著に小さくなっていることがわかる。すなわち、Th1に比較してTh2が大きい場合に腫瘍の存在が疑われ、Th3の値が大きいことによって悪性腫瘍の存在が疑われる。さらに、良性腫瘍の場合、各Th反応のパラダイムパターンを表現型および内在型で比較すると、表現型のものではTh3では、基準線より上に相関係数の値が位置しているのに対して、内在型ものでは基準線より下に相関係数の値が位置している。悪性腫瘍の場合は、Th3の相関係数の値は表現型および内在型とも基準線より上に位置している。これによっても、悪性腫瘍および良性腫瘍の区別が可能となる。
Claims (13)
- 哺乳動物のTh1、Th2、及びTh3の各細胞内のサイトカインを測定する工程と、各サイトカインのパラダイムパターンを求める工程と、パラダイムパターンと疾患とを関連付ける工程と、を備える、哺乳動物のサイトカインの分析方法。
- 前記パラダイムパターンに基づいて、特定疾患に罹患する可能性を決定する請求項1記載の方法。
- 前記パラダイムパターンと特定疾患の予防又は治療を関連付ける請求項1又は2記載の方法。
- 前記Th1、Th2、及びTh3のサイトカインが順番に、主としてインターフェロン−γ、インターロイキン−4、TGF−β1である請求項1記載の方法。
- 前記Th1、Th2、及びTh3の少なくとも一つのあるいは複数のTh反応を制御する薬剤を投与する工程を含む請求項1記載の方法。
- 前記サイトカインを測定する工程は、体液中と細胞内の前記サイトカインを測定する工程を備える、請求項1記載の方法。
- 前記サイトカインを測定する工程は、表現型Th反応と細胞内在型Th反応を測定する工程を備える、請求項1記載の方法。
- 前記パラダイムパターンに、レドックス制御、TGF-β1の活性化の行程の評価結果、NK及び/又はNKT細胞活性の測定値の少なくとも一つを組み合わせて、疾患を関連付ける請求項1の方法。
- レドックス制御が表現型あるいは細胞内在型TGF-β1に規定される前記Th3反応を調整する請求項1又は3記載の方法。
- 哺乳動物のTh1、Th2、及びTh3の各サイトカインを測定する第1工程と、測定値をコンピュータに入力する第2工程と、コンピュータを用いて各サイトカイン反応のパラダイムパターンを求める第3工程と、前記パラダイムパターンをモニタに表示する工程と、コンピュータの演算手段が、当該パラダイムパターンと、予めメモリに記憶された、各疾患に於ける既知のパラダイムパターンとを比較する第4工程と、を備える、哺乳動物のサイトカイン、Th反応の型ならびに感染症などの病態の分析方法。
- コンピュータの演算手段が、前記比較の結果、測定されたパラダイムパターンの図示化から、測定対象個体の疾患或いは疾患の病態とその治療・方法を特定する第5工程を備える請求項10記載の方法。
- Th反応が変化する疾患、とくにTh1/2/3病に対するTh1/2反応のパターンとレドックス制御、Th1/2/3反応のパターンによりクロストークすることと、これに基づいた治療法。
- Th3サイトカインである表現型TGF-β1の増加と異常な上昇の確認と、これに関連したTh3反応の優位性(増強)、さらにレドックス制御の偏重固定化、その結果誘導される細胞内型Th1反応とTh2反応のアンバランスならびに反応性の低下に基づくテーラーメイド療法の評価方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007504833A JP5252682B2 (ja) | 2005-02-25 | 2006-02-27 | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005051809 | 2005-02-25 | ||
JP2005051809 | 2005-02-25 | ||
JP2007504833A JP5252682B2 (ja) | 2005-02-25 | 2006-02-27 | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 |
PCT/JP2006/303577 WO2006090874A1 (ja) | 2005-02-25 | 2006-02-27 | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006090874A1 true JPWO2006090874A1 (ja) | 2008-07-24 |
JP5252682B2 JP5252682B2 (ja) | 2013-07-31 |
Family
ID=36927504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007504833A Active JP5252682B2 (ja) | 2005-02-25 | 2006-02-27 | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5252682B2 (ja) |
WO (1) | WO2006090874A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6207157B2 (ja) * | 2010-09-24 | 2017-10-04 | 株式会社 バイオエルティ | Th3マーチ関連疾患の治療及び予防用医薬組成物 |
EP2607899B1 (en) * | 2011-12-21 | 2016-08-10 | Beckman Coulter, Inc. | Method for labeling intracellular and extracellular targets of leukocytes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1094828A4 (en) * | 1998-05-07 | 2005-01-26 | Univ California | USE OF TARGETED, NEGLIGATED TISSUE ANTIGENS TO MODULATE IMMUNE REACTIONS |
EP1138692A1 (en) * | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
-
2006
- 2006-02-27 JP JP2007504833A patent/JP5252682B2/ja active Active
- 2006-02-27 WO PCT/JP2006/303577 patent/WO2006090874A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP5252682B2 (ja) | 2013-07-31 |
WO2006090874A1 (ja) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Leung et al. | The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype | |
Gustafson et al. | Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis | |
Hessam et al. | Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS) | |
Smits et al. | Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome | |
Lanni et al. | Conformationally altered p53: a novel Alzheimer's disease marker? | |
Czarnowicki et al. | Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases | |
CN107636468A (zh) | 用于预测认知退化的风险的方法 | |
EP1998789A2 (en) | Biomarkers for amyotrophic lateral sclerosis and methods using the same | |
JP2017535763A (ja) | マーカー群および該マーカー群の脳損傷における使用 | |
Shimauchi et al. | Serum interleukin‐22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis | |
Peter et al. | Impaired resolution of inflammation in the Endoglin heterozygous mouse model of chronic colitis | |
Möllerherm et al. | Hypoxia modulates the response of mast cells to Staphylococcus aureus infection | |
JP2016530536A (ja) | 療法に対する奏効性の決定方法 | |
Watkins et al. | Extensive phenotypic characterisation of a human TDP-43Q331K transgenic mouse model of amyotrophic lateral sclerosis (ALS) | |
Félix Garza et al. | Characterization of disease-specific cellular abundance profiles of chronic inflammatory skin conditions from deconvolution of biopsy samples | |
Abe et al. | Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database | |
Baruca et al. | Single fiber EMG as a prognostic tool in myasthenia gravis | |
Costa et al. | Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis | |
Wimmer et al. | Microglia pre-activation and neurodegeneration precipitate neuroinflammation without exacerbating tissue injury in experimental autoimmune encephalomyelitis | |
JP5252682B2 (ja) | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 | |
Luft et al. | Heritable aspects of salt sensitivity | |
Calabresi et al. | Measuring treatment response to advance precision medicine for multiple sclerosis | |
Pavelek et al. | The role of the immune system and the biomarker CD3+ CD4+ CD45RA− CD62L− in the pathophysiology of migraine | |
Balion et al. | Brain type carnosinase in dementia: a pilot study | |
Kuiper et al. | A network of serum proteins predict the need for systemic immunomodulatory therapy at diagnosis in noninfectious uveitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120907 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130401 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130415 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5252682 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160426 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |